Fish Oil May Slow Schizophrenia

Omega-3 supplementation reduced progression rates among people with early-stage symptoms of schizophrenia, according to a small trial.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, ODDMAN47Seven years ago, investigators enrolled 81 people aged 13 to 25 with early signs of schizophrenia in a clinical trial to test the effects of omega-3 fish oil pills. A paper published this week (August 11) in Nature Communications reported on 71 of those participants, pointing to a notable benefit of the supplements: only 10 percent of those taking fish oils ultimately developed schizophrenia, compared with 40 percent of the placebo group.

“I don’t want to sound like a cynic or a skeptic, but it’s almost too good to be true,” psychiatrist Jeffrey Lieberman of Columbia University Medical Center in New York City who was not involved in the study told ScienceNews.

Schizophrenia usually starts to manifest in the first 20 to 30 years of life, with minor delusions and paranoid thoughts often occurring in the teenage years or younger. But only about a third of people who present with such early symptoms eventually develop psychosis, New Scientist reported. After researchers found that the blood cells of schizophrenia patients have lower levels of omega-3 fatty acids than those of healthy controls, scientists in the field began to investigate the possibility that supplementing these compounds could treat the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies